vs

Side-by-side financial comparison of Peraso Inc. (PRSO) and Roivant Sciences Ltd. (ROIV). Click either name above to swap in a different company.

Peraso Inc. is the larger business by last-quarter revenue ($2.9M vs $2.0M, roughly 1.4× Roivant Sciences Ltd.). Peraso Inc. runs the higher net margin — -43.3% vs -13301.2%, a 13257.9% gap on every dollar of revenue. On growth, Peraso Inc. posted the faster year-over-year revenue change (-22.0% vs -77.8%). Over the past eight quarters, Peraso Inc.'s revenue compounded faster (1.0% CAGR vs -73.7%).

Peraso Inc. is a semiconductor technology firm specializing in the design and production of high-performance millimeter wave (mmWave) integrated circuits and modules. It delivers 5G and next-generation wireless connectivity solutions for telecom infrastructure, industrial IoT, fixed wireless access and consumer electronics segments, serving customers across North America, Asia Pacific and European markets.

Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel.

PRSO vs ROIV — Head-to-Head

Bigger by revenue
PRSO
PRSO
1.4× larger
PRSO
$2.9M
$2.0M
ROIV
Growing faster (revenue YoY)
PRSO
PRSO
+55.9% gap
PRSO
-22.0%
-77.8%
ROIV
Higher net margin
PRSO
PRSO
13257.9% more per $
PRSO
-43.3%
-13301.2%
ROIV
Faster 2-yr revenue CAGR
PRSO
PRSO
Annualised
PRSO
1.0%
-73.7%
ROIV

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
PRSO
PRSO
ROIV
ROIV
Revenue
$2.9M
$2.0M
Net Profit
$-1.2M
$-265.9M
Gross Margin
52.2%
Operating Margin
-44.6%
-16966.1%
Net Margin
-43.3%
-13301.2%
Revenue YoY
-22.0%
-77.8%
Net Profit YoY
20.3%
-257.0%
EPS (diluted)
$-0.09
$-0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PRSO
PRSO
ROIV
ROIV
Q4 25
$2.9M
$2.0M
Q3 25
$3.2M
$1.6M
Q2 25
$2.2M
$2.2M
Q1 25
$3.9M
$-39.6M
Q4 24
$3.7M
$9.0M
Q3 24
$3.8M
$4.5M
Q2 24
$4.2M
$8.0M
Q1 24
$2.8M
$28.9M
Net Profit
PRSO
PRSO
ROIV
ROIV
Q4 25
$-1.2M
$-265.9M
Q3 25
$-1.2M
$-113.5M
Q2 25
$-1.8M
$-223.4M
Q1 25
$-471.0K
$-206.5M
Q4 24
$-1.6M
$169.4M
Q3 24
$-2.7M
$-230.2M
Q2 24
$-4.4M
$95.3M
Q1 24
$-2.0M
$-151.1M
Gross Margin
PRSO
PRSO
ROIV
ROIV
Q4 25
52.2%
Q3 25
56.2%
Q2 25
48.3%
Q1 25
69.3%
Q4 24
56.3%
Q3 24
47.0%
Q2 24
55.5%
Q1 24
46.4%
Operating Margin
PRSO
PRSO
ROIV
ROIV
Q4 25
-44.6%
-16966.1%
Q3 25
-36.8%
-19492.9%
Q2 25
-80.0%
-13130.0%
Q1 25
-13.3%
674.8%
Q4 24
-44.3%
-3042.6%
Q3 24
-70.3%
-7636.0%
Q2 24
-105.6%
-1279.5%
Q1 24
-128.9%
-919.5%
Net Margin
PRSO
PRSO
ROIV
ROIV
Q4 25
-43.3%
-13301.2%
Q3 25
-37.4%
-7225.9%
Q2 25
-82.4%
-10292.9%
Q1 25
-12.2%
521.8%
Q4 24
-42.4%
1878.3%
Q3 24
-70.6%
-5143.8%
Q2 24
-104.4%
1192.7%
Q1 24
-72.1%
-522.3%
EPS (diluted)
PRSO
PRSO
ROIV
ROIV
Q4 25
$-0.09
$-0.38
Q3 25
$-0.17
$-0.17
Q2 25
$-0.31
$-0.33
Q1 25
$-0.10
$-0.28
Q4 24
$0.36
$0.23
Q3 24
$-0.98
$-0.31
Q2 24
$-1.88
$0.12
Q1 24
$-1.07
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PRSO
PRSO
ROIV
ROIV
Cash + ST InvestmentsLiquidity on hand
$2.9M
$4.5B
Total DebtLower is stronger
Stockholders' EquityBook value
$4.6M
$4.3B
Total Assets
$6.1M
$5.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PRSO
PRSO
ROIV
ROIV
Q4 25
$2.9M
$4.5B
Q3 25
$4.4B
Q2 25
$4.5B
Q1 25
$4.9B
Q4 24
$3.3M
$5.1B
Q3 24
$1.3M
$5.4B
Q2 24
$1.9M
$5.7B
Q1 24
$2.4M
$6.5B
Total Debt
PRSO
PRSO
ROIV
ROIV
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
$311.7M
Q1 24
$430.6M
Stockholders' Equity
PRSO
PRSO
ROIV
ROIV
Q4 25
$4.6M
$4.3B
Q3 25
$3.6M
$4.4B
Q2 25
$3.0M
$4.3B
Q1 25
$3.6M
$4.7B
Q4 24
$3.5M
$5.2B
Q3 24
$2.0M
$5.2B
Q2 24
$3.6M
$5.4B
Q1 24
$6.7M
$6.0B
Total Assets
PRSO
PRSO
ROIV
ROIV
Q4 25
$6.1M
$5.2B
Q3 25
$6.2M
$5.1B
Q2 25
$5.5M
$5.0B
Q1 25
$6.7M
$5.4B
Q4 24
$7.2M
$5.8B
Q3 24
$7.2M
$6.2B
Q2 24
$9.8M
$6.5B
Q1 24
$11.5M
$7.2B
Debt / Equity
PRSO
PRSO
ROIV
ROIV
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
0.06×
Q1 24
0.07×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PRSO
PRSO
ROIV
ROIV
Operating Cash FlowLast quarter
$-1.1M
$-196.5M
Free Cash FlowOCF − Capex
$-201.4M
FCF MarginFCF / Revenue
-10076.0%
Capex IntensityCapex / Revenue
246.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-776.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PRSO
PRSO
ROIV
ROIV
Q4 25
$-1.1M
$-196.5M
Q3 25
$-1.5M
$-185.7M
Q2 25
$-2.0M
$-204.4M
Q1 25
$-966.0K
$-172.6M
Q4 24
$-687.0K
$-207.3M
Q3 24
$-683.0K
$-266.8M
Q2 24
$-659.0K
$-192.8M
Q1 24
$-2.5M
$-108.5M
Free Cash Flow
PRSO
PRSO
ROIV
ROIV
Q4 25
$-201.4M
Q3 25
$-1.6M
$-193.5M
Q2 25
$-208.4M
Q1 25
$-173.4M
Q4 24
$-209.1M
Q3 24
$-267.8M
Q2 24
$-193.8M
Q1 24
$-108.8M
FCF Margin
PRSO
PRSO
ROIV
ROIV
Q4 25
-10076.0%
Q3 25
-48.9%
-12317.8%
Q2 25
-9604.5%
Q1 25
438.1%
Q4 24
-2318.5%
Q3 24
-5984.4%
Q2 24
-2425.5%
Q1 24
-376.1%
Capex Intensity
PRSO
PRSO
ROIV
ROIV
Q4 25
246.9%
Q3 25
1.1%
499.6%
Q2 25
185.9%
Q1 25
-2.0%
Q4 24
20.3%
Q3 24
22.3%
Q2 24
12.1%
Q1 24
1.2%
Cash Conversion
PRSO
PRSO
ROIV
ROIV
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-1.22×
Q3 24
Q2 24
-2.02×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PRSO
PRSO

Products$2.8M96%
Other$105.0K4%

ROIV
ROIV

Segment breakdown not available.

Related Comparisons